Senomyx has been awarded US Patent No. 7,052,857, "Expression of functional human olfactory cyclic nucleotide gated channel in recombinant host cells and use thereof in cell-based assays to identify GPCR modulators."
Inventors listed on the patent are Mark Zoller, Hong Xu, Lena Staszewski, Bryan Moyer, Alexey Pronin, Jon Elliot Adler, Guy Servant, and Nicholas Callamaras.
According to its abstract, the patent protects isolated nucleic acid sequences that encode human olfactory cyclic nucleotide gated (CNG) channel subunits, and the corresponding polypeptides. The invention further relates to the use of human CNG channels to profile, screen for, and identify compounds that modulate the human olfactory CNG channel. More specifically, the invention relates to the expression of the human olfactory CNG channel in cells, preferably mammalian cells, and the use of these cells in high throughput cell-based assays to identify compounds that enhance or block human olfactory CNG function. Compounds that activate the olfactory CNG channel will enhance smell and can be used to make foods more palatable for individuals with attenuated olfactory function. Conversely, compounds that inhibit the olfactory CNG channel will inhibit smell and can be use to block malodors. Additionally, the invention relates to the use of cell-based olfactory CNG channel assays to identify modulators of G-protein coupled receptor and other proteins that regulate cyclic nucleotide levels, the abstract states.
The Whitehead Institute for Biomedical Research has been awarded US Patent No. 7,052,870, "mTOR kinase-associated proteins."
Inventors listed on the patent are David Sabatini, Do-Hyung Kim, and Dos Sarbassov.
According to its abstract, the patent protects isolated mTOR-associated proteins (mTOR-APs) as well as isolated variants and fragments thereof and the isolated nucleic acids encoding them. The invention also describes vectors and host cells containing nucleic acid encoding an mTOR-AP polypeptide and methods for producing an mTOR-AP polypeptide. Also described are methods for screening for compounds that modulate mTOR-AP activity and methods for treating or preventing a disorder that is responsive to mTOR-AP modulation, the abstract states.
The Council of Scientific and Industrial Research in New Delhi, India, has been awarded US Patent No. 7,052,910, "Skeletal cell model to screen anti-diabetic compounds."
Inventors listed on the patent are Naresh Kumar and Chinmoy Dey.
According to its abstract, the patent protects the development of an insulin-resistant skeletal muscle cell-culture model useful for screening compounds that enhance insulin receptor and insulin receptor substrate-1 tyrosine phosphorylation required against type II diabetes.